Last reviewed · How we verify

NCT04650321

Home Based Infusions for Ocrelizumab

Recruiting now Phase 4 Last updated 10 June 2021
What this trial tests

Phase 4 trial testing Ocrelizumab at home in Multiple Sclerosis in 110 participants. Currently enrolling.

Timeline
1 March 2021
Primary endpoint
31 August 2021
31 August 2021

Quick facts

Lead sponsorUniversity of Colorado, Denver
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment110
Start date1 March 2021
Primary completion31 August 2021
Estimated completion31 August 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 55, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
    Barrera B, Simpson H, Engebretson E, Sillau S, et al · · 2023 · cited 7× · PMID 36811392 · DOI 10.1002/acn3.51745
  2. Trends of Decentralized Clinical Trials Using Digital Technology for Decentralization
    Sato T, Mizumoto S, Ota M, Shikano M. · · 2022 · DOI 10.2139/ssrn.4243284

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing